• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Patient-reported outcomes and experiences of migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite treatment dispensation: the 'ASAP' study.参与多学科 HIV 诊所、可快速、免费、现场提供治疗的移民患者报告的结果和体验:'ASAP' 研究。
AIDS Res Ther. 2024 Jun 18;21(1):40. doi: 10.1186/s12981-024-00632-5.
2
Impact of social determinants of health on time to antiretroviral therapy initiation and HIV viral undetectability for migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite B/F/TAF: 'The ASAP study'.社会决定因素对接受快速、免费、现场提供的 B/F/TAF 的多学科 HIV 诊所入组的移民进行抗逆转录病毒治疗启动和 HIV 病毒不可检测的时间的影响:'ASAP 研究'。
HIV Med. 2024 May;25(5):600-607. doi: 10.1111/hiv.13608. Epub 2024 Jan 11.
3
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.简报:比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺在女性 HIV 感染者中的疗效和安全性:5 项试验的综合分析。
J Acquir Immune Defic Syndr. 2021 Dec 1;88(4):393-398. doi: 10.1097/QAI.0000000000002789.
4
Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.比克替拉韦/恩曲他滨/丙酚替诺福韦艾拉酚胺作为快速启动护理模式下初治 HIV 患者的一线治疗:BIC-NOW 临床试验。
Int J Antimicrob Agents. 2024 Jun;63(6):107164. doi: 10.1016/j.ijantimicag.2024.107164. Epub 2024 Apr 2.
5
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.从多替拉韦加阿巴卡韦和拉米夫定转换为固定剂量比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺治疗病毒学抑制的 HIV-1 成人患者:一项随机、双盲、多中心、活性对照、3 期、非劣效性临床试验的 48 周结果。
Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18.
6
Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 year.比克替拉韦、恩曲他滨和丙酚替诺福韦艾拉酚胺联合治疗 HIV 感染者:至 1 年 BICSTaR 研究的通俗易懂报告。
Future Microbiol. 2024;19(15):1273-1282. doi: 10.1080/17460913.2024.2391190. Epub 2024 Sep 4.
7
Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.中国贵阳成年人中比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺用于 HIV 暴露后预防的安全性和依从性:一项前瞻性队列研究。
BMC Infect Dis. 2024 Jun 6;24(1):565. doi: 10.1186/s12879-024-09407-9.
8
Comments on "High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence".对“比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺(B/F/TAF)在美国黑人成年人中具有高效性,包括那些已有HIV耐药性和依从性欠佳的患者”的评论
J Med Virol. 2024 Oct;96(10):e29950. doi: 10.1002/jmv.29950.
9
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.比克替拉韦与多替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯用于 HIV-1 感染初始治疗的双盲、随机、2 期临床试验
Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15.
10
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺与多替拉韦、阿巴卡韦和拉米夫定用于治疗人类免疫缺陷病毒 1 型感染的初始治疗(GS-US-380-1489):一项双盲、多中心、3 期、随机、对照非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.

引用本文的文献

1
Understanding care experiences amongst immigrant and refugee clients in a Ryan-White funded HIV clinic.了解瑞安·怀特基金资助的艾滋病诊所中移民和难民客户的护理体验。
Commun Med (Lond). 2025 Jun 10;5(1):225. doi: 10.1038/s43856-025-00879-7.

本文引用的文献

1
Impact of social determinants of health on time to antiretroviral therapy initiation and HIV viral undetectability for migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite B/F/TAF: 'The ASAP study'.社会决定因素对接受快速、免费、现场提供的 B/F/TAF 的多学科 HIV 诊所入组的移民进行抗逆转录病毒治疗启动和 HIV 病毒不可检测的时间的影响:'ASAP 研究'。
HIV Med. 2024 May;25(5):600-607. doi: 10.1111/hiv.13608. Epub 2024 Jan 11.
2
A people-centred health system must be the foundation for person-centred care in the HIV response.以人为本的卫生系统必须成为艾滋病应对中以患者为中心的照护的基础。
J Int AIDS Soc. 2023 Jul;26 Suppl 1(Suppl 1):e26125. doi: 10.1002/jia2.26125.
3
Experiences of Migrant People Living with HIV in a Multidisciplinary HIV Care Setting with Rapid B/F/TAF Initiation and Cost-Covered Treatment: The 'ASAP' Study.在多学科艾滋病护理环境中快速启动B/F/TAF并提供费用覆盖治疗的艾滋病毒感染流动人群的经历:“ASAP”研究
J Pers Med. 2022 Sep 13;12(9):1497. doi: 10.3390/jpm12091497.
4
Brief Report: It's Time to Embed Health-Related Quality of Life Across all Steps of the HIV Care Cascade.简短报告:是时候将与健康相关的生活质量纳入艾滋病毒治疗全过程的各个环节了。
J Acquir Immune Defic Syndr. 2022 Nov 1;91(3):251-254. doi: 10.1097/QAI.0000000000003051.
5
Satisfaction with access to health services among foreign-born population in Finland: a survey-based study.芬兰出生的外国人口对获取卫生服务的满意度:一项基于调查的研究。
BMC Health Serv Res. 2022 Jun 15;22(1):781. doi: 10.1186/s12913-022-08155-3.
6
"I die silently inside". Qualitative findings from a study of people living with HIV who migrate to and settle in Canada.“我在内心默默死去”。一项关于移民并定居加拿大的艾滋病毒感染者的研究的定性研究结果。
J Migr Health. 2022 Mar 11;5:100088. doi: 10.1016/j.jmh.2022.100088. eCollection 2022.
7
Biopsychosocial approach to understanding determinants of depression among men who have sex with men living with HIV: A systematic review.从生物-心理-社会角度理解感染 HIV 的男男性行为者抑郁决定因素:系统综述。
PLoS One. 2022 Mar 14;17(3):e0264636. doi: 10.1371/journal.pone.0264636. eCollection 2022.
8
Small studies, big decisions: the role of pilot/feasibility studies in incremental science and premature scale-up of behavioral interventions.小型研究,重大决策:试点/可行性研究在行为干预的渐进式科学及过早扩大规模中的作用。
Pilot Feasibility Stud. 2021 Sep 10;7(1):173. doi: 10.1186/s40814-021-00909-w.
9
Barriers and Facilitators Affecting the HIV Care Cascade for Migrant People Living with HIV in Organization for Economic Co-Operation and Development Countries: A Systematic Mixed Studies Review.经济合作与发展组织国家中影响艾滋病毒感染者移民接受艾滋病毒护理连续性服务的障碍和促进因素:系统混合研究综述。
AIDS Patient Care STDS. 2021 Aug;35(8):288-307. doi: 10.1089/apc.2021.0079.
10
Recruitment and Retention of Women Living With HIV for Clinical Research: A Review.招募和留住感染艾滋病毒的女性参与临床研究:综述。
AIDS Behav. 2021 Oct;25(10):3267-3278. doi: 10.1007/s10461-021-03273-1. Epub 2021 May 14.

参与多学科 HIV 诊所、可快速、免费、现场提供治疗的移民患者报告的结果和体验:'ASAP' 研究。

Patient-reported outcomes and experiences of migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite treatment dispensation: the 'ASAP' study.

机构信息

Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada.

Centre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve Blvd - Office 3C.25, Montreal, QC, H4A 3S5, Canada.

出版信息

AIDS Res Ther. 2024 Jun 18;21(1):40. doi: 10.1186/s12981-024-00632-5.

DOI:10.1186/s12981-024-00632-5
PMID:38890671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11184703/
Abstract

BACKGROUND

Scholars recommend providing migrants living with HIV (MLWH) with free treatment, rapidly, once linked to care to optimize their HIV-related experiences and health outcomes. Quantitative evaluations of patient-reported measures for MLWH in such models are necessary to explore the viability of these recommendations.

METHODS

Within a 96-week prospective cohort study at a multidisciplinary HIV clinic, participants received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for free and rapidly following care linkage. Eight patient-reported measures were administered at weeks 4, 24, and 48: (1) mMOS-SS to measure perceived social support; (2) IA-RSS to measure internalized stigma; (3) K6 to measure psychological distress; (4) PROMIS to measure self-efficacy with treatment taking; (5) G-MISS to measure perceived compliance with clinicians' treatment plans; (6) HIVTSQ to measure treatment satisfaction; (7) CARE to measure perceived provider empathy; and (8) PRPCC to measure perceived clinician cultural competence. Linear mixed modelling with bootstrapping was conducted to identify significant differences by sociodemographics and time.

RESULTS

Across weeks 4, 24, and 48, results suggest that MLWH enrolled in this study experienced moderate levels of social support; elevated levels of HIV-related stigma; moderate levels of distress; high self-efficacy with daily medication self-management; great compliance with clinicians' treatment plans; high treatment satisfaction; high perceived empathy; and high perceived cultural competence. Experience of social support (i.e., mMOS-SS scores) differed significantly by birth region. Experience of HIV-related stigma (i.e., IA-RSS scores) differed significantly by birth region, age, and language. Experience of distress (i.e., K6 scores) differed significantly by sexual orientation. Experience of treatment satisfaction (i.e., HIVTSQ scores) differed significantly by birth region and age. No significant differences were identified by time for any measure.

CONCLUSION

Overall, participants expressed positive experiences around treatment and care, alongside comparably lower perceptions of social support, internalized stigma, and distress, potentially underscoring a need to embed targeted, well-funded, and accessible mental health support within HIV care models.

摘要

背景

学者们建议为感染艾滋病病毒的移民(MLWH)提供免费治疗,快速治疗,一旦与护理联系起来,以优化他们与艾滋病病毒相关的体验和健康结果。有必要对这些模型中 MLWH 的患者报告措施进行定量评估,以探索这些建议的可行性。

方法

在一个多学科的艾滋病毒诊所的 96 周前瞻性队列研究中,参与者在获得护理联系后立即免费获得比替拉韦/恩曲他滨/丙酚替诺福韦(B/F/TAF)。在第 4、24 和 48 周时,共进行了 8 项患者报告的测量:(1)mMOS-SS 用于衡量感知社会支持;(2)IA-RSS 用于衡量内化的耻辱感;(3)K6 用于衡量心理困扰;(4)PROMIS 用于衡量自我效能感与治疗依从性;(5)G-MISS 用于衡量对临床医生治疗计划的遵守情况;(6)HIVTSQ 用于衡量治疗满意度;(7)CARE 用于衡量感知提供者的同理心;(8)PRPCC 用于衡量感知临床医生的文化能力。采用带有自举的线性混合模型,根据社会人口统计学和时间确定显著差异。

结果

在第 4、24 和 48 周,结果表明,参加这项研究的 MLWH 经历了中等水平的社会支持;艾滋病毒相关耻辱感较高;中度心理困扰;自我效能感高,日常用药自我管理能力强;高度遵守临床医生的治疗计划;治疗满意度高;感知同理心强;感知文化能力强。社会支持体验(即 mMOS-SS 评分)因出生地区而异有显著差异。艾滋病毒相关耻辱感体验(即 IA-RSS 评分)因出生地区、年龄和语言而异有显著差异。心理困扰体验(即 K6 评分)因性取向而异有显著差异。治疗满意度体验(即 HIVTSQ 评分)因出生地区和年龄而异有显著差异。没有任何测量指标在时间上有显著差异。

结论

总体而言,参与者对治疗和护理表示积极的体验,同时对社会支持、内化的耻辱感和困扰的感知相对较低,这可能强调需要在艾滋病毒护理模式中嵌入有针对性、资金充足且可获得的心理健康支持。